A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise
NCT ID: NCT00118690
Last Updated: 2016-09-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
227 participants
INTERVENTIONAL
2003-12-31
2005-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise
NCT00118716
Treatment Of Symptomatic Asthma In Children
NCT00197106
A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise
NCT01435902
Study Of Asthma In Patients Of African Descent
NCT00102765
Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)
NCT00127166
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fluticasone propionate/salmeterol
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Experience worsened asthma symptoms during physical activity.
* Using or used an inhaled steroid for the last 4 weeks or longer (such as Aerobid, Azmacort, Flovent, Pulmicort, QVAR, or Vanceril).
Exclusion Criteria
* Have only intermittent, seasonal, or exercise induced asthma, and not persistent asthma.
* Admitted to a hospital within the last 6 months due to asthma symptoms.
* Any poorly controlled medical conditions that may make study participation unsafe or inappropriate in the opinion of the study physician (such as cystic fibrosis, congenital heart disease, insulin dependent diabetes, glaucoma, drug allergies, etc.).
* The study physician will evaluate other medical criteria.
4 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Jonesboro, Arkansas, United States
GSK Investigational Site
East Artesia, California, United States
GSK Investigational Site
Huntington Beach, California, United States
GSK Investigational Site
Long Beach, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Madera, California, United States
GSK Investigational Site
Mission Viejo, California, United States
GSK Investigational Site
Oakland, California, United States
GSK Investigational Site
Rolling Hills Est, California, United States
GSK Investigational Site
Vista, California, United States
GSK Investigational Site
Denver, Colorado, United States
GSK Investigational Site
Englewood, Colorado, United States
GSK Investigational Site
Pueblo, Colorado, United States
GSK Investigational Site
Altamonte Springs, Florida, United States
GSK Investigational Site
Delray Beach, Florida, United States
GSK Investigational Site
St. Petersburg, Florida, United States
GSK Investigational Site
Tampa, Florida, United States
GSK Investigational Site
Tampa, Florida, United States
GSK Investigational Site
Lawrenceville, Georgia, United States
GSK Investigational Site
Marietta, Georgia, United States
GSK Investigational Site
Savannah, Georgia, United States
GSK Investigational Site
Savannah, Georgia, United States
GSK Investigational Site
Normal, Illinois, United States
GSK Investigational Site
Iowa City, Iowa, United States
GSK Investigational Site
Louisville, Kentucky, United States
GSK Investigational Site
Sunset, Louisiana, United States
GSK Investigational Site
Bethesda, Maryland, United States
GSK Investigational Site
Boston, Massachusetts, United States
GSK Investigational Site
Robbinsdale, Minnesota, United States
GSK Investigational Site
Missoula, Montana, United States
GSK Investigational Site
Omaha, Nebraska, United States
GSK Investigational Site
Mount Laurel, New Jersey, United States
GSK Investigational Site
Kernersville, North Carolina, United States
GSK Investigational Site
Oklahoma City, Oklahoma, United States
GSK Investigational Site
Medford, Oregon, United States
GSK Investigational Site
Altoona, Pennsylvania, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, United States
GSK Investigational Site
Upland, Pennsylvania, United States
GSK Investigational Site
Charleston, South Carolina, United States
GSK Investigational Site
Mt. Pleasant, South Carolina, United States
GSK Investigational Site
Orangeburg, South Carolina, United States
GSK Investigational Site
Nashville, Tennessee, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
El Paso, Texas, United States
GSK Investigational Site
El Paso, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Layton, Utah, United States
GSK Investigational Site
Provo, Utah, United States
GSK Investigational Site
South Burlington, Vermont, United States
GSK Investigational Site
Burke, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Clinical Study Report
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Study Protocol
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Dataset Specification
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Individual Participant Data Set
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Informed Consent Form
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
http://www.findclinicalstudy.com
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SFA100316
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.